Inclusion Criteria:

          1. Part A: Previously treated subjects with recurrent and/or metastatic NSCLC, pancreatic
             cancer, ovarian cancer, papillary thyroid cancer, colorectal adenocarcinoma and
             melanoma with documented progression/intolerance following at least one previous
             therapy (and not more than 2 previous regimens);

          2. Part B: Subjects with histologically confirmed metastatic or locally advanced
             non-small cell lung cancer (NSCLC) with documented progression following
             anti-PD-1/PD-L1 containing therapy; Subjects must have confirmation of progression of
             disease that is consistent with iCPD during or within 3 months of prior anti-PD1/PDL1
             with either two radiographic scans showing disease progression or documented clinical
             progression (e.g., worsening of symptoms); Subjects could have had a maximum of 1
             prior treatment regimen;

          3. Part C: Subjects with histologically confirmed metastatic pancreatic adenocarcinoma as
             defined by NCCN Guidelines; Subjects with islet cell neoplasms are excluded; Subjects
             could have had a maximum of 1 prior treatment regimen for metastatic disease excluding
             nab-paclitaxel containing regimens and up to 8 weeks from last chemotherapy treatment;
             nab-paclitaxel completed more than 6 months prior to study is allowed.

          4. Must have at least 1 measurable lesion per RECIST1.1 with progressing or new tumors
             since last antitumor therapy;

          5. ECOG performance status score of 0 or 1;

          6. Adequate safety lab results;

          7. Stable brain metastases;

          8. WCBP (Women of Childbearing Potential) must have a negative serum pregnancy test at
             Screening and a negative urine pregnancy test, WCBP must agree to abstain from sex or
             use an adequate method of contraception, males must abstain from sex with WCBP or use
             an adequate method of contraception.

        Exclusion Criteria:

          1. Part A: Received more than two prior systemic regimens for the metastatic disease

          2. Part B and C: Received more than 1 prior systemic regimens for the advanced/recurrent
             and/or metastatic disease

          3. History of weight loss >10% over the 2 months prior to Screening;

          4. Concurrent malignancy requiring treatment;

          5. Active, untreated central nervous system (CNS) metastases;

          6. Subjects previously treated with an anti PD-1/PD-L1 targeting agent with history
             immune mediated toxicity;

          7. Severely immunocompromised;

          8. History of allergy or hypersensitivity to any of the study treatment components;

          9. Major surgery within 4 weeks of study administration;

         10. Clinically relevant serious co-morbid medical conditions including, but not limited
             to:

               -  Active infection;

               -  Recent (within six months of Screening) cardiac disease, myocardial infarction,
                  or severe or unstable angina;

               -  History of serious arrhythmia;

               -  Chronic obstructive or chronic restrictive pulmonary disease, pulmonary
                  hypertension history of or active interstitial lung disease or pneumonitis;

               -  Prior organ allograft;

               -  Subjects with active, known or suspected autoimmune disease;

               -  History of active or latent tuberculosis infection;

               -  Positive test for HIV, HBV, or HCV;

         11. Radiation within two weeks prior to the first study treatment;

         12. Treatment with another investigational therapy within 30 days or 5 half-lives of the
             drug prior to Screening, whichever is longer;

         13. Treatment with botanical preparations (e.g., herbal supplements or traditional Chinese
             medicines) intended for general health support or to treat the disease under study
             within 2 weeks prior to treatment;

         14. Pregnant or lactating women.